

MSc Neuromuscular Disease

View Online



-
1.
Blottner D, Salanova M. The neuromuscular system: from earth to space life science : neuromuscular cell signalling in disuse and exercise [Internet]. Vol. Springer briefs in space life sciences. Cham: Springer; 2015. Available from:
<http://UCL.ebib.com/patron/FullRecord.aspx?p=1967380>
 2.
Benson MKD. Children's neuromuscular disorders. London: Springer; 2011.
 3.
Shaibani A. A Video Atlas of Neuromuscular Disorders [Internet]. Oxford University Press; 2014. Available from:
<http://www.oxfordmedicine.com/view/10.1093/med/9780199898152.001.0001/med-9780199898152>
 4.
Hilton-Jones D, Turner MR, editors. Oxford textbook of neuromuscular disorders [Internet]. Vol. Oxford textbooks in clinical neurology. [Oxford]: Oxford University Press; 2014. Available from: <http://dx.doi.org/10.1093/med/9780199698073.001.0001>
 5.
Kernell D. The Motoneurone and its Muscle Fibres [Internet]. Oxford University Press; 2006. Available from:
<http://www.oxfordscholarship.com/view/10.1093/acprof:oso/9780198526551.001.0001/acprof-9780198526551>

6.

Amato AA, Russell JA. Neuromuscular disorders. New York: McGraw-Hill; 2008.

7.

Jain KK, editor. Applied neurogenomics [Internet]. Vol. Neuromethods. New York, NY: Humana Press; 2015. Available from: <http://dx.doi.org/10.1007/978-1-4939-2247-5>

8.

Davies AM. Regulation of Neuronal Survival by Neurotrophins in the Developing Peripheral Nervous System. In: Patterning and Cell Type Specification in the Developing CNS and PNS [Internet]. Elsevier; 2013. p. 303–11. Available from: <http://linkinghub.elsevier.com/retrieve/pii/B9780123972651000952>

9.

Gordon T, Sulaiman OA. Nerve Regeneration in the Peripheral Nervous System. In: Kettenmann H, editor. Neuroglia [Internet]. Oxford University Press; 2012. p. 701–14. Available from: <http://www.oxfordmedicine.com/view/10.1093/med/9780199794591.001.0001/med-9780199794591-chapter-55>

10.

Welch MB, Brummett CM. Peripheral Nervous System Anatomy and Function. In: Mashour GA, Lydic R, editors. Neuroscientific Foundations of Anesthesiology [Internet]. Oxford University Press; 2011. p. 133–40. Available from: <http://oxfordmedicine.com/view/10.1093/med/9780195398243.001.0001/med-9780195398243-chapter-010>

11.

Rossor AM, Tomaselli PJ, Reilly MM. Recent advances in the genetic neuropathies. Current Opinion in Neurology. 2016 Sept;

12.

Rossor AM, Evans MRB, Reilly MM. A practical approach to the genetic neuropathies. *Practical Neurology*. 2015 June;15(3):187–98.

13.

AM Rossor. Recent advances in the genetic neuropathies. *Current opinion in neurology* [Internet]. 2016;29(5). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130159/>

14.

Reilly M, Fridman V. Inherited Neuropathies. *Seminars in Neurology*. 2015 Oct 6;35(04):407–23.

15.

Rossor AM, Evans MRB, Reilly MM. A practical approach to the genetic neuropathies. *Practical Neurology*. 2015 June;15(3):187–98.

16.

Pasterkamp RJ. Getting neural circuits into shape with semaphorins. *Nature Reviews Neuroscience*. 2012 Aug 16;13(9):605–18.

17.

R Klein. Role of neurotrophins in mouse neuronal development. *The FASEB Journal* [Internet]. 1994;8(10):738–44. Available from: <http://www.fasebj.org/content/8/10/738.long>

18.

Schlosser G. Induction and specification of cranial placodes. *Developmental Biology*. 2006 June;294(2):303–51.

19.

Thiede-Stan NK, Schwab ME. Attractive and repulsive factors act through multi-subunit

receptor complexes to regulate nerve fiber growth. *Journal of Cell Science*. 2015 July 15;128(14):2403–14.

20.

Irina Dudanova. Genetic Evidence for a Contribution of EphA:EphrinA Reverse Signaling to Motor Axon Guidance. *Journal of Neuroscience* [Internet]. 2012;32(15):5209–15. Available from: <http://www.jneurosci.org/content/32/15/5209>

21.

Wang L, Klein R, Zheng B, Marquardt T. Anatomical Coupling of Sensory and Motor Nerve Trajectory via Axon Tracking. *Neuron*. 2011 July;71(2):263–77.

22.

Van Battum EY, Brignani S, Pasterkamp RJ. Axon guidance proteins in neurological disorders. *The Lancet Neurology*. 2015 May;14(5):532–46.

23.

Kao TJ, Law C, Kania A. Eph and ephrin signaling: Lessons learned from spinal motor neurons. *Seminars in Cell & Developmental Biology*. 2012 Feb;23(1):83–91.

24.

Byung-Yong Park. Induction and Segregation of the Vertebrate Cranial Placodes. 2010; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK53175/>

25.

Taniguchi M, Yuasa S, Fujisawa H, Naruse I, Saga S, Mishina M, et al. Disruption of Semaphorin III/D Gene Causes Severe Abnormality in Peripheral Nerve Projection. *Neuron*. 1997 Sept;19(3):519–30.

26.

Ebens A, Brose K, Leonardo ED, Jr MGH, Bladt F, Birchmeier C, et al. Hepatocyte Growth

Factor/Scatter Factor Is an Axonal Chemoattractant and a Neurotrophic Factor for Spinal Motor Neurons. *Neuron*. 1996 Dec;17(6):1157-72.

27.

A. Caton. The branchial arches and HGF are growth-promoting and chemoattractant for cranial motor axons. *Development* [Internet]. 127(8):1751-66. Available from: <http://dev.biologists.org/content/127/8/1751.long>

28.

Conover JC, Erickson JT, Katz DM, Bianchi LM, Poueymirou WT, McClain J, et al. Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4. *Nature*. 1995 May;375(6528):235-8.

29.

Jessen KR, Mirsky R. The origin and development of glial cells in peripheral nerves. *Nature Reviews Neuroscience*. 2005 Sept;6(9):671-82.

30.

Monk KR, Feltri ML, Taveggia C. New insights on schwann cell development. *Glia*. 2015 Aug;63(8):1376-93.

31.

Jessen KR, Mirsky R, Lloyd AC. Schwann Cells: Development and Role in Nerve Repair. *Cold Spring Harbor Perspectives in Biology*. 2015 July;7(7).

32.

Salzer JL. Schwann Cell Myelination. *Cold Spring Harbor Perspectives in Biology*. 2015 Aug;7(8).

33.

Arthur-Farraj PJ, Latouche M, Wilton DK, Quintes S, Chabrol E, Banerjee A, et al. c-Jun

Reprograms Schwann Cells of Injured Nerves to Generate a Repair Cell Essential for Regeneration. *Neuron*. 2012 Aug;75(4):633–47.

34.

Brosius Lutz A, Barres BA. Contrasting the Glial Response to Axon Injury in the Central and Peripheral Nervous Systems. *Developmental Cell*. 2014 Jan;28(1):7–17.

35.

Jessen KR, Mirsky R. The repair Schwann cell and its function in regenerating nerves. *The Journal of Physiology*. 2016 July 1;594(13):3521–31.

36.

Auer-Grumbach M. Hereditary sensory and autonomic neuropathies. In: *Peripheral Nerve Disorders* [Internet]. Elsevier; 2013. p. 893–906. Available from: <http://linkinghub.elsevier.com/retrieve/pii/B9780444529022000503>

37.

Davidson GL, Murphy SM, Polke JM, Laura M, Salih MAM, Muntoni F, et al. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. *Journal of Neurology*. 2012 Aug;259(8):1673–85.

38.

Rossor AM, Evans MRB, Reilly MM. A practical approach to the genetic neuropathies. *Practical Neurology*. 2015 June;15(3):187–98.

39.

Chhabra A. Peripheral MR Neurography. *Neuroimaging Clinics of North America*. 2014 Feb;24(1):79–89.

40.

Purves D. *Neuroscience* [Internet]. Bethesda: National Library of Medicine; 2001. Available

from:
<http://www.ncbi.nlm.nih.gov/books/bv.fcgi?call=bv.View..ShowTOC&rid=neurosci.TOC&depth=2>

41.

Effects of axon diameter and myelination (video) | Khan Academy [Internet]. Available from:
<https://www.khanacademy.org/science/health-and-medicine/nervous-system-and-sensory-infor/neuron-membrane-potentials-2014-03-27T17:58:17.207Z/v/effects-of-axon-diameter-and-myelination>

42.

Nerve Signaling [Internet]. Available from:
https://www.nobelprize.org/educational/medicine/nerve_signaling/index.html

43.

Duncan JS, Winston GP, Koepp MJ, Ourselin S. Brain imaging in the assessment for epilepsy surgery. *The Lancet Neurology*. 2016 Apr;15(4):420–33.

44.

Nowell M, Sparks R, Zombori G, Miserocchi A, Rodionov R, Diehl B, et al. Resection planning in extratemporal epilepsy surgery using 3D multimodality imaging and intraoperative MRI. *British Journal of Neurosurgery*. 2017 July 4;31(4):468–70.

45.

Vakharia VN, Sparks R, O'Keeffe AG, Rodionov R, Miserocchi A, McEvoy A, et al. Accuracy of intracranial electrode placement for stereoelectroencephalography: A systematic review and meta-analysis. *Epilepsia*. 2017 June;58(6):921–32.

46.

Michell A. Understanding EMG [Internet]. Oxford University Press; 2013. Available from:
<http://oxfordmedicine.com/view/10.1093/med/9780199595501.001.0001/med-9780199595501>

47.

Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations. 3rd ed. London: Elsevier Saunders; 2013.

48.

Top tips for writing a lay summary | The Academy of Medical Sciences [Internet]. Available from: <https://acmedsci.ac.uk/more/news/10-tips-for-writing-a-lay-summary>

49.

How to Write a Lay Summary | Digital Curation Centre [Internet]. Available from: <http://www.dcc.ac.uk/resources/how-guides/write-lay-summary>

50.

Free guides [Internet]. Available from: <http://www.plainenglish.co.uk/free-guides.html>

51.

Part two - The specifics - Access to Understanding [Internet]. Available from: <http://www.access2understanding.org/guidance/part-two-the-specifics/>

52.

Readable | Free Readability Test Tool [Internet]. Available from: <https://www.webpagefx.com/tools/read-able/>

53.

Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. *Journal of Neurology, Neurosurgery & Psychiatry*. 2004 June 1;75(suppl_2):ii43-50.

54.

Antoine JC, Camdessanché JP. Paraneoplastic disorders of the peripheral nervous system. *La Presse Médicale*. 2013 June;42(6):e235–44.

55.

How to Write a Lay Summary | DCC How-to Guides [Internet]. Available from: <http://www.dcc.ac.uk/resources/how-guides/>

56.

Rossor AM, Evans MRB, Reilly MM. A practical approach to the genetic neuropathies. *Practical Neurology*. 2015 June;15(3):187–98.

57.

Rossor AM, Kalmar B, Greensmith L, Reilly MM. The distal hereditary motor neuropathies. *Journal of Neurology, Neurosurgery & Psychiatry*. 2012 Jan;83(1):6–14.

58.

Rossor AM, Carr AS, Devine H, Chandrashekar H, Pelayo-Negro AL, Pareyson D, et al. Peripheral neuropathy in complex inherited diseases: an approach to diagnosis. *Journal of Neurology, Neurosurgery & Psychiatry*. 2017 Oct;88(10):846–63.

59.

Carr AS, Pelayo-Negro AL, Evans MR, Laurà M, Blake J, Stancanelli C, et al. A study of the neuropathy associated with transthyretin amyloidosis (ATTR) in the UK. *Journal of Neurology, Neurosurgery & Psychiatry*. 2016 June;87(6):620–7.

60.

Hawkins PN, Ando Y, Dispenzeri A, Gonzalez-Duarte A, Adams D, Suhr OB. Evolving landscape in the management of transthyretin amyloidosis. *Annals of Medicine*. 2015 Nov 17;47(8):625–38.

61.

Plante-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). *Neurology*. 2007 Aug 14;69(7):693–8.

62.

Dubrey S, Ackermann E, Gillmore J. The transthyretin amyloidoses: advances in therapy. *Postgraduate Medical Journal*. 2015 Aug;91(1078):439–48.

63.

Dimachkie MM, Barohn RJ. Guillain-Barré Syndrome and Variants. *Neurologic Clinics*. 2013 May;31(2):491–510.

64.

Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. *The Lancet*. 2016 Aug;388(10045):717–27.

65.

Collins MP, Hadden RD. The nonsystemic vasculitic neuropathies. *Nature Reviews Neurology*. 2017 Apr 27;13(5):302–16.

66.

Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. *Annals of the Rheumatic Diseases*. 2016 Sept;75(9):1583–94.

67.

Collins MP, Dyck PJB, Gronseth GS, Guillevin L, Hadden RDM, Heuss D, et al. Peripheral Nerve Society Guideline* on the classification, diagnosis, investigation, and immunosuppressive therapy of non-systemic vasculitic neuropathy: executive summary. *Journal of the Peripheral Nervous System*. 2010 Sept;15(3):176–84.

68.

Berthelsen MP, Husu E, Christensen SB, Prahm KP, Vissing J, Jensen BR. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. *Neuromuscular Disorders*. 2014 June;24(6):492-8.

69.

Cup EH, Pieterse AJ, ten Broek-Pastoor JM, Munneke M, van Engelen BG, Hendricks HT, et al. Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. *Archives of Physical Medicine and Rehabilitation*. 2007 Nov;88(11):1452-64.

70.

Strength training and aerobic exercise training for muscle disease - van der Kooi - 2005 - The Cochrane Library - Wiley Online Library. Available from:
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003907.pub2/abstract?systemMessage=Wiley+Online+Library+usage+report+download+page+will+be+unavailable+on+Friday+24th+November+2017+at+21%3A00+EST+%2F+02.00+GMT+%2F+10%3A00+SGT+%28Saturday+25th+Nov+for+SGT+>

71.

Sveen ML, Andersen SP, Ingelsrud LH, Blichter S, Olsen NE, Jønck S, et al. Resistance training in patients with limb-girdle and becker muscular dystrophies. *Muscle & Nerve*. 2013 Feb;47(2):163-9.

72.

Jeppesen TD, Schwartz M, Olsen DB, Wibrand F, Krag T, Duno M, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. *Brain*. 2006 June 9;129(12):3402-12.

73.

Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses - *European Journal of Physical and Rehabilitation Medicine* 2013 April;49(2):169-78 - *Minerva Medica - Journals* [Internet]. Available from: <https://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2013N02A0169>

74.

Michael P. Wiggs. Can endurance exercise preconditioning prevention disuse muscle atrophy? *Frontiers in Physiology* [Internet]. 2015;6. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356230/>

75.

Keith Baar. Using Molecular Biology to Maximize Concurrent Training. *Sports Medicine (Auckland, N.z)* [Internet]. 2014;44(Suppl 2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4213370/>

76.

Craig DM, Ashcroft SP, Belew MY, Stocks B, Currell K, Baar K, et al. Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. *Frontiers in Physiology*. 2015 Oct 27;6.

77.

Hoier B, Hellsten Y. Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. *Microcirculation*. 2014 May;21(4):301-14.

78.

Hardie DG. AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle. *Physiology*. 2006 Feb 1;21(1):48-60.

79.

Hawley JA, Hargreaves M, Joyner MJ, Zierath JR. Integrative Biology of Exercise. *Cell*. 2014 Nov;159(4):738-49.

80.

Jones DA, Haan A de, Round JM. *Skeletal muscle from molecules to movement: a textbook of muscle physiology for sport, exercise, physiotherapy and medicine*. Edinburgh: Churchill Livingstone; 2004.

81.

A. M. Gordon. Regulation of Contraction in Striated Muscle. *Physiological Reviews* [Internet]. 2000 Jan 4;80(2):853–924. Available from: <http://physrev.physiology.org/content/80/2/853.long>

82.

R Bottinelli. Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. *The Journal of Physiology* [Internet]. 1996;495(Pt 2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1160815/>

83.

Harridge SDR, Bottinelli R, Canepari M, Pellegrino MA, Reggiani C, Esbjörnsson M, et al. Whole-muscle and single-fibre contractile properties and myosin heavy chain isoforms in humans. *Pflügers Archiv - European Journal of Physiology*. 1996 Sept;432(5):913–20.

84.

By: Hunter, S (Hunter, S); White, M (White, M); Thompson, M (Thompson, M). Techniques to evaluate elderly human muscle function: A physiological basis. *JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES* *JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES* [Internet]. 1998;53(3). Available from: https://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=6&SID=E3HXcKOaUmhvHimfaQi&page=1&doc=1

85.

O'Brien TD, Reeves ND, Baltzopoulos V, Jones DA, Maganaris CN. In vivo measurements of muscle specific tension in adults and children. *Experimental Physiology*. 2010 Jan 1;95(1):202–10.

86.

Clarke C, Howard R, Rossor M, Shorvon SD, National Hospital for Neurology and Neurosurgery (London, England), Institute of Neurology, Queen Square. *Neurology: a Queen Square textbook* [Internet]. Chichester: Wiley-Blackwell; 2009. Available from: <http://onlinelibrary.wiley.com/book/10.1002/9781444311709>

87.

Neuromuscular Disease Centre [Internet]. Available from: <http://neuromuscular.wustl.edu/>

88.

Richard J. Barohn. A PATTERN RECOGNITION APPROACH TO THE PATIENT WITH A SUSPECTED MYOPATHY. *Neurologic clinics* [Internet]. 2014;32(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233647/>

89.

Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. *European Radiology*. 2010 Oct;20(10):2447-60.

90.

Morrow JM, Sinclair CDJ, Fischmann A, Machado PM, Reilly MM, Yousry TA, et al. MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study. *The Lancet Neurology*. 2016 Jan;15(1):65-77.

91.

Briggs D, Morgan JE. Recent progress in satellite cell/myoblast engraftment - relevance for therapy. *FEBS Journal*. 2013 Sept;280(17):4281-93.

92.

Peter S. Zammit. Muscle satellite cells adopt divergent fates: a mechanism for self-renewal? *The Journal of Cell Biology* [Internet]. 2004;166(3). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2172269/>

93.

Boldrin L, Morgan JE. Activating muscle stem cells: therapeutic potential in muscle diseases. *Current Opinion in Neurology*. 2007 Oct;20(5):577-82.

94.

Boldrin L, Zammit PS, Morgan JE. Satellite cells from dystrophic muscle retain regenerative capacity. *Stem Cell Research*. 2015 Jan;14(1):20–9.

95.

Ross J, Benn A, Jonuschies J, Boldrin L, Muntoni F, Hewitt JE, et al. Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large Mouse. *STEM CELLS*. 2012 Oct;30(10):2330–41.

96.

Ravenscroft G, Davis MR, Lamont P, Forrest A, Laing NG. New era in genetics of early-onset muscle disease: Breakthroughs and challenges. *Seminars in Cell & Developmental Biology*. 2017 Apr;64:160–70.

97.

Ravenscroft G, Laing NG, Bönnemann CG. Pathophysiological concepts in the congenital myopathies: blurring the boundaries, sharpening the focus. *Brain*. 2015 Feb;138(2):246–68.

98.

North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, et al. Approach to the diagnosis of congenital myopathies. *Neuromuscular Disorders*. 2014 Feb;24(2):97–116.

99.

Quijano-Roy S, Carlier RY, Fischer D. Muscle Imaging in Congenital Myopathies. *Seminars in Pediatric Neurology*. 2011 Dec;18(4):221–9.

100.

Kimberly Amburgey. A natural history study of X-linked myotubular myopathy. *Neurology [Internet]*. 2017;89(13). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649758/>

101.

Irene Colombo. Congenital myopathies: Natural history of a large pediatric cohort. *Neurology* [Internet]. 2015;84(1). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336094/>

102.

Guidance for Paediatric Physiotherapists - Managing Neuromuscular Disorders [Internet]. Available from: <http://apcp.csp.org.uk/publications/guidance-paediatric-physiotherapists-managing-neuromuscular-disorders>

103.

APCP [Internet]. Available from: <http://apcp.csp.org.uk/>

104.

Neuromuscular | Department of Neurology [Internet]. Available from: <https://neuro.wustl.edu/education/fellowships/neuromuscular/>

105.

Muscular Dystrophy UK [Internet]. Available from: <http://www.muscardystrophyuk.org/>

106.

Hollak CEM, Lachmann R, editors. *Inherited metabolic disease in adults: a clinical guide* [Internet]. [New York]: Oxford University Press; 2016. Available from: <http://dx.doi.org/10.1093/med/9780199972135.001.0001>

107.

Saudubray JM, Baumgartner MR, Walter J, editors. *Inborn metabolic diseases: diagnosis and treatment*. 6th edition. Berlin: Springer; 2016.

108.

Hoffmann GF, Zschocke J, Nyhan WL. Inherited metabolic diseases: a clinical approach [Internet]. Heidelberg: Springer; 2009. Available from: <http://dx.doi.org/10.1007/978-3-540-74723-9>

109.

Machado P, Brady S, Hanna MG. Update in inclusion body myositis. *Current Opinion in Rheumatology*. 2013 Nov;25(6):763–71.

110.

Machado PM, Dimachkie MM, Barohn RJ. Sporadic inclusion body myositis. *Current Opinion in Neurology*. 2014 Oct;27(5):591–8.

111.

Machado PM, Ahmed M, Brady S, Gang Q, Healy E, Morrow JM, et al. Ongoing Developments in Sporadic Inclusion Body Myositis. *Current Rheumatology Reports*. 2014 Dec;16(12).

112.

Mhoriam Ahmed. Targeting Protein Homeostasis in Sporadic Inclusion Body Myositis. *Science translational medicine* [Internet]. 2016;8(331). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043094/>

113.

Needham M, Mastaglia FL. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. *Clinical Neurophysiology*. 2016 Mar;127(3):1764–73.

114.

Schröder R, Schoser B. Myofibrillar Myopathies: A Clinical and Myopathological Guide. *Brain Pathology*. 2009 July;19(3):483–92.

115.

Amato AA, Greenberg SA. Inflammatory Myopathies. CONTINUUM: Lifelong Learning in Neurology. 2013 Dec;19:1615–33.

116.

Olivé M, Kley RA, Goldfarb LG. Myofibrillar myopathies. Current Opinion in Neurology. 2013 Oct;26(5):527–35.

117.

Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clinical & Experimental Immunology. 2014 Mar;175(3):349–58.

118.

Dalakas MC. Inflammatory Muscle Diseases. New England Journal of Medicine. 2015 Apr 30;372(18):1734–47.

119.

Great Britain. Audit Commission for Local Authorities and the National Health Service in England and Wales. What Seems to Be the Matter Communication (National Health Service Report). Stationery Office;

120.

T. D. Bunker. An information leaflet for surgical patients. Annals of The Royal College of Surgeons of England [Internet]. 1983;65(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2494353/>

121.

Toolkit for producing patient information.pdf [Internet]. Available from: <https://www.uea.ac.uk/documents/246046/0/Toolkit+for+producing+patient+information.pdf>

122.

Garner M, Ning Z, Francis J. A framework for the evaluation of patient information leaflets. *Health Expectations*. 2012 Sept;15(3):283–94.

123.

C F George. Prescription information leaflets: a pilot study in general practice. *British Medical Journal (Clinical research ed)* [Internet]. 1983;287(6400). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1549423/>

124.

Hollingsworth KG, de Sousa PL, Straub V, Carlier PG. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France. *Neuromuscular Disorders*. 2012 Oct;22:S54–67.

125.

Wattjes MP, Fischer D. *Neuromuscular imaging* [Internet]. New York: Springer; 2013. Available from: <https://www.dawsonera.com/abstract/9781461465522>

126.

Forbes SC, Willcocks RJ, Triplett WT, Rooney WD, Lott DJ, Wang DJ, et al. Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study. *PLoS ONE*. 2014 Sept 9;9(9).

127.

Glover GH, Schneider E. Three-point dixon technique for true water/fat decomposition with B0 inhomogeneity correction. *Magnetic Resonance in Medicine*. 1991 Apr;18(2):371–83.

128.

Willcocks RJ, Rooney WD, Triplett WT, Forbes SC, Lott DJ, Senesac CR, et al. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. *Annals of Neurology*. 2016 Apr;79(4):535–47.

129.

Jean-Yves Hogrel. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. *Neurology [Internet]*. 2016;86(11). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799716/>

130.

American Journal of Roentgenology. Available from: <http://www.ajronline.org/doi/abs/10.2214/AJR.14.13755>

131.

Hollak CEM, Lachmann R, editors. *Inherited metabolic disease in adults: a clinical guide [Internet]*. [New York]: Oxford University Press; 2016. Available from: <http://dx.doi.org/10.1093/med/9780199972135.001.0001>

132.

Nancy D Leslie. *Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency*. 2014; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK6816/>

133.

Thomas Wieser. *Carnitine Palmitoyltransferase II Deficiency*. 2017; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1253/>

134.

Miguel A Martín. *Glycogen Storage Disease Type V*. 2014; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1344/>

135.

Nancy Leslie. Pompe Disease. 2017; Available from:
<https://www.ncbi.nlm.nih.gov/books/NBK1261/>

136.

Ørngreen MC, Vissing J. Treatment Opportunities in Patients With Metabolic Myopathies. Current Treatment Options in Neurology. 2017 Nov;19(11).

137.

Olpin SE, Murphy E, Kirk RJ, Taylor RW, Quinlivan R. The investigation and management of metabolic myopathies. Journal of Clinical Pathology. 2015 June;68(6):410–7.

138.

Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet Neurology. 2003 Dec;2(12):731–40.

139.

Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology. 2010 Jan;9(1):77–93.

140.

Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology. 2010 Feb;9(2):177–89.

141.

Ricotti V, Ridout DA, Scott E, Quinlivan R, Robb SA, Manzur AY, et al. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry. 2013 June 1;84(6):698–705.

142.

Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhardt PF, Heuvelmans N, et al. Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy. *New England Journal of Medicine*. 2011 Apr 21;364(16):1513-22.

143.

Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. *Annals of Neurology*. 2013 Nov;74(5):637-47.

144.

Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, Shao J, et al. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. *Annals of Neurology*. 2016 Feb;79(2):257-71.

145.

Kinali M, Arechavala-Gomez V, Feng L, Cirak S, Hunt D, Adkin C, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. *The Lancet Neurology*. 2009 Oct;8(10):918-28.

146.

Cirak S, Arechavala-Gomez V, Guglieri M, Feng L, Torelli S, Anthony K, et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. *The Lancet*. 2011 Aug;378(9791):595-605.

147.

Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. *Muscle & Nerve*. 2014 Oct;50(4):477-87.

148.

Victorian Department of Health / University of Melbourne [Internet]. Available from: <https://www2.health.vic.gov.au/>

149.

Best Practice in Memory Services: Learning from across England [Internet]. Available from: <https://www.england.nhs.uk/wp-content/uploads/2014/12/memory-clinics-final.pdf>

150.

Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. *Brain*. 2010 Jan;133(1):9-22.

151.

Venance SL, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, et al. The primary periodic paralyses: diagnosis, pathogenesis and treatment. *Brain*. 2006 Jan 1;129(1):8-17.

152.

Cannon SC. Channelopathies of Skeletal Muscle Excitability. In: Terjung R, editor. *Comprehensive Physiology* [Internet]. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2011. p. 761-90. Available from: <http://doi.wiley.com/10.1002/cphy.c140062>

153.

Tan SV, Matthews E, Barber M, Burge JA, Rajakulendran S, Fialho D, et al. Refined exercise testing can aid dna-based diagnosis in muscle channelopathies. *Annals of Neurology*. 2011 Feb;69(2):328-40.

154.

Sharp L, Trivedi JR. Treatment and Management of Neuromuscular Channelopathies. *Current Treatment Options in Neurology*. 2014 Oct;16(10).

155.

Paganoni S, Amato A. Electrodiagnostic Evaluation of Myopathies. *Physical Medicine and Rehabilitation Clinics of North America*. 2013 Feb;24(1):193-207.

156.

Fuglsang-Frederiksen A. The role of different EMG methods in evaluating myopathy. *Clinical Neurophysiology*. 2006 June;117(6):1173–89.

157.

Ferlini A, Scotton C, Novelli G. Biomarkers in Rare Diseases. *Public Health Genomics*. 2013;16(6):313–21.

158.

Boers, M (Boers, M); Brooks, P (Brooks, P); Strand, CV (Strand, CV); Tugwell, P (Tugwell, P). The OMERACT filter for outcome measures in rheumatology. *JOURNAL OF RHEUMATOLOGY* [Internet]. 1998;25(2):198–9. Available from: <https://contentstore.cla.co.uk/secure/link?id=caecd7db-09ea-e611-80c9-005056af4099>

159.

Conwit RA, Bhanushali MJ, Porter JD, Kaufmann P, Gutmann L. Adding more muscle and nerve to clinical trials. *Muscle & Nerve*. 2011 Nov;44(5):695–702.

160.

Qualification Process for Drug Development Tools [Internet]. Available from: <https://www.fda.gov/downloads/drugs/guidances/ucm230597.pdf>

161.

Ahmed M, Machado PM, Miller A, Spicer C, Herbelin L, He J, et al. Targeting protein homeostasis in sporadic inclusion body myositis. *Science Translational Medicine*. 2016 Mar 23;8(331):331ra41–331ra41.

162.

A Cruz-Martínez. Single fiber electromyography (SFEMG) in mitochondrial diseases (MD). *Electromyography and clinical neurophysiology*. 2004;

163.

Hull J, Aniapravan R, Chan E, Chatwin M, Forton J, Gallagher J, et al. British Thoracic Society guideline for respiratory management of children with neuromuscular weakness. *Thorax*. 2012 July;67(Suppl 1):i1-40.

164.

American Journal of Respiratory and Critical Care Medicine. Available from: <http://www.atsjournals.org/doi/abs/10.1164/ajrccm.161.1.9901057>

165.

Ward S. Randomised controlled trial of non-invasive ventilation (NIV) for nocturnal hypoventilation in neuromuscular and chest wall disease patients with daytime normocapnia. *Thorax*. 2005 Dec 1;60(12):1019-24.

166.

Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial. *The Lancet Neurology*. 2015 Sept;14(9):883-92.

167.

Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. *Journal of Neurochemistry*. 2016 Aug;138:6-31.

168.

Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. *Journal of Neurochemistry*. 2016 Aug;138:193-210.

169.

Li L, Xiong WC, Mei L. Neuromuscular Junction Formation, Aging, and Disorders. *Annual Review of Physiology*. 2018 Feb 10;80(1).

170.

Singhal N, Martin PT. Role of extracellular matrix proteins and their receptors in the development of the vertebrate neuromuscular junction. *Developmental Neurobiology*. 2011 Nov;71(11):982–1005.

171.

Nishimune H, Valdez G, Jarad G, Moulson CL, Müller U, Miner JH, et al. Laminins promote postsynaptic maturation by an autocrine mechanism at the neuromuscular junction. *The Journal of Cell Biology*. 2008 Sept 22;182(6):1201–15.

172.

Nishimune H. Active zones of mammalian neuromuscular junctions: formation, density, and aging. *Annals of the New York Academy of Sciences*. 2012 Dec;1274(1):24–32.

173.

Rudolf R, Khan MM, Labeit S, Deschenes MR. Degeneration of Neuromuscular Junction in Age and Dystrophy. *Frontiers in Aging Neuroscience*. 2014 May 22;6.

174.

Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. *Amyotrophic Lateral Sclerosis*. 2012 Jan;13(1):1–10.

175.

Simon NG, Turner MR, Vucic S, Al-Chalabi A, Shefner J, Lomen-Hoerth C, et al. Quantifying disease progression in amyotrophic lateral sclerosis. *Annals of Neurology*. 2014 Nov;76(5):643–57.

176.

Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. *Neurology*. 2015 June 2;84(22):2247–57.

177.

Caballero-Hernandez D, Toscano MG, Cejudo-Guillen M, Garcia-Martin ML, Lopez S, Franco JM, et al. The 'Omics' of Amyotrophic Lateral Sclerosis. *Trends in Molecular Medicine*. 2016 Jan;22(1):53-67.

178.

Michael Benatar. ALS Biomarkers for Therapy Development: State of the Field & Future Directions. *Muscle & nerve* [Internet]. 2016;53(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718795/>

179.

Ulf Andreasson. Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders. *Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring* [Internet]. 2016;3. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941042/>

180.

Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, et al. The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans. *Alzheimer's & Dementia*. 2015 July;11(7):772-91.

181.

Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. *Nature Reviews Neurology*. 2016 Dec 16;13(2):96-104.

182.

Carrì MT, D'Ambrosi N, Cozzolino M. Pathways to mitochondrial dysfunction in ALS pathogenesis. *Biochemical and Biophysical Research Communications*. 2017 Feb;483(4):1187-93.

183.

Lin G, Mao D, Bellen HJ. Amyotrophic Lateral Sclerosis Pathogenesis Converges on Defects in Protein Homeostasis Associated with TDP-43 Mislocalization and Proteasome-Mediated Degradation Overload. In: Fly Models of Human Diseases [Internet]. Elsevier; 2017. p. 111-71. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S0070215316301454>

184.

Monahan Z, Shewmaker F, Pandey UB. Stress granules at the intersection of autophagy and ALS. *Brain Research*. 2016 Oct;1649:189-200.

185.

Ruegsegger C, Saxena S. Proteostasis impairment in ALS. *Brain Research*. 2016 Oct;1648:571-9.

186.

Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. *Nature Neuroscience*. 2014 Jan;17(1):17-23.

187.

Jessell TM. Neuronal specification in the spinal cord: inductive signals and transcriptional codes. *Nature Reviews Genetics*. 2000 Oct;1(1):20-9.

188.

Harland R. Neural induction. *Current Opinion in Genetics & Development*. 2000 Aug;10(4):357-62.

189.

Dasen JS, Jessell TM. Chapter Six Hox Networks and the Origins of Motor Neuron Diversity. In: *Hox Genes* [Internet]. Elsevier; 2009. p. 169-200. Available from: <http://linkinghub.elsevier.com/retrieve/pii/S007021530988006X>

190.

Bonanomi D, Pfaff SL. Motor Axon Pathfinding. *Cold Spring Harbor Perspectives in Biology*. 2010 Mar 1;2(3):a001735–a001735.

191.

Darabid H, Perez-Gonzalez AP, Robitaille R. Neuromuscular synaptogenesis: coordinating partners with multiple functions. *Nature Reviews Neuroscience*. 2014 Nov;15(11):703–18.

192.

Kanning KC, Kaplan A, Henderson CE. Motor Neuron Diversity in Development and Disease. *Annual Review of Neuroscience*. 2010 June;33(1):409–40.

193.

Ladle DR, Pecho-Vrieseling E, Arber S. Assembly of Motor Circuits in the Spinal Cord: Driven to Function by Genetic and Experience-Dependent Mechanisms. *Neuron*. 2007 Oct;56(2):270–83.

194.

Robert M. Brownstone. Spinal interneurons providing input to the final common path during locomotion. *Progress in brain research* [Internet]. 2010;187. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3150186/>

195.

O'Connor E, Töpf A, Zahedi R, Spendiff S, Cox D, Roos A, et al. Clinical and research strategies for limb-girdle congenital myasthenic syndromes. *Annals of the New York Academy of Sciences*. 2018 Jan 5;

196.

Andrew G. Engel. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. *The Lancet Neurology* [Internet]. 2015;14(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4520251/>

197.

Cruz PMR, Palace J, Beeson D. Congenital myasthenic syndromes and the neuromuscular junction. *Current Opinion in Neurology*. 2014 Oct;27(5):566–75.

198.

Rodríguez Cruz PM, Palace J, Beeson D. Inherited disorders of the neuromuscular junction: an update. *Journal of Neurology*. 2014 Nov;261(11):2234–43.

199.

Belaya K, Rodríguez Cruz PM, Liu WW, Maxwell S, McGowan S, Farrugia ME, et al. Mutations in *CHST3* cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies. *Brain*. 2015 Sept;138(9):2493–504.

200.

Rodríguez Cruz PM, Sewry C, Beeson D, Jayawant S, Squier W, McWilliam R, et al. Congenital myopathies with secondary neuromuscular transmission defects; A case report and review of the literature. *Neuromuscular Disorders*. 2014 Dec;24(12):1103–10.

201.

Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. *Nature Reviews Neuroscience*. 2016 Feb;17(2):103–17.

202.

Gilhus NE. Myasthenia Gravis. *New England Journal of Medicine*. 2016 Dec 29;375(26):2570–81.

203.

Matthew N Meriggioli. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. *Lancet neurology* [Internet]. 2009;8(5). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730933/>

204.

Spillane J, Beeson DJ, Kullmann DM. Myasthenia and related disorders of the neuromuscular junction. *Journal of Neurology, Neurosurgery & Psychiatry*. 2010 Aug 1;81(8):850–7.

205.

Orrell, Richard WBarclay, Chris. Diagnosis and management of motor neurone disease. *Practitioner* [Internet]. 260:17–21. Available from: <https://search.proquest.com/docview/1844334383?OpenUrlRefId=info:xri/sid:primo&aaccountid=14511>

206.

Morgan S, Orrell RW. Pathogenesis of amyotrophic lateral sclerosis. *British Medical Bulletin*. 2016 Sept;119(1):87–98.

207.

Fuller G, Manford M. *Neurology: an illustrated colour text* [Internet]. 3rd ed. Edinburgh: Churchill Livingstone; 2010. Available from: <https://www.dawsonera.com/guard/protected/dawson.jsp?name=https://shib-idp.ucl.ac.uk/shibboleth&dest=http://www.dawsonera.com/depp/reader/protected/external/AbstractView/S9780702048883>

208.

Couratier P, Corcia P, Lautrette G, Nicol M, Preux PM, Marin B. Epidemiology of amyotrophic lateral sclerosis: A review of literature. *Revue Neurologique*. 2016 Jan;172(1):37–45.

209.

Motor neurone disease: assessment and management | Guidance and guidelines | NICE. Available from: <https://www.nice.org.uk/guidance/ng42>

210.

Vincent A. Timeline: Unravelling the pathogenesis of myasthenia gravis. *Nature Reviews*

Immunology. 2002 Oct;2(10):797-804.

211.

Leslie Jacobson. Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. *Journal of Clinical Investigation* [Internet]. 1999;103(7). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC408264/>

212.

Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. *Nature Medicine*. 2001 Mar;7(3):365-8.

213.

Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. *Journal of Anatomy*. 2014 Jan;224(1):29-35.

214.

Viegas S, Jacobson L, Waters P, Cossins J, Jacob S, Leite MI, et al. Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. *Experimental Neurology*. 2012 Apr;234(2):506-12.

215.

Koneczny I, Cossins J, Waters P, Beeson D, Vincent A. MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. *PLoS ONE*. 2013 Nov 7;8(11).

216.

Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. *Nature Reviews Neuroscience*. 2016 Feb;17(2):103-17.

217.

Beryl B. Cummings. Improving genetic diagnosis in Mendelian disease with transcriptome sequencing. *Science translational medicine* [Internet]. 2017;9(386). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548421/>

218.

Schofield D, Alam K, Douglas L, Shrestha R, MacArthur DG, Davis M, et al. Cost-effectiveness of massively parallel sequencing for diagnosis of paediatric muscle diseases. *npj Genomic Medicine*. 2017 Dec;2(1).

219.

O'Grady GL, Lek M, Lamande SR, Waddell L, Oates EC, Punetha J, et al. Diagnosis and etiology of congenital muscular dystrophy: We are halfway there. *Annals of Neurology*. 2016 July;80(1):101-11.

220.

Bönnemann CG, Wang CH, Quijano-Roy S, Deconinck N, Bertini E, Ferreiro A, et al. Diagnostic approach to the congenital muscular dystrophies. *Neuromuscular Disorders*. 2014 Apr;24(4):289-311.

221.

North KN, Wang CH, Clarke N, Jungbluth H, Vainzof M, Dowling JJ, et al. Approach to the diagnosis of congenital myopathies. *Neuromuscular Disorders*. 2014 Feb;24(2):97-116.

222.

Menezes MP, North KN. Inherited neuromuscular disorders: Pathway to diagnosis. *Journal of Paediatrics and Child Health*. 2012 June;48(6):458-65.

223.

Milestones timeline : Nature Milestones in DNA [Internet]. Available from: <https://www.nature.com/milestones/miledna/timeline.html>

224.

Metzker ML. Sequencing technologies — the next generation. *Nature Reviews Genetics*. 2010 Jan;11(1):31–46.

225.

Yang Y, Muzny DM, Reid JG, Bainbridge MN, Willis A, Ward PA, et al. Clinical Whole-Exome Sequencing for the Diagnosis of Mendelian Disorders. *New England Journal of Medicine*. 2013 Oct 17;369(16):1502–11.

226.

Sun Y, Ruivenkamp CAL, Hoffer MJV, Vrijenhoek T, Kriek M, van Asperen CJ, et al. Next-Generation Diagnostics: Gene Panel, Exome, or Whole Genome? *Human Mutation*. 2015 June;36(6):648–55.

227.

Ghaoui R, Cooper ST, Lek M, Jones K, Corbett A, Reddel SW, et al. Use of Whole-Exome Sequencing for Diagnosis of Limb-Girdle Muscular Dystrophy. *JAMA Neurology*. 2015 Dec 1;72(12).

228.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in Medicine*. 2015 May;17(5):405–23.

229.

Gabrielle Natalie Samuel. The UK's 100,000 Genomes Project: manifesting policymakers' expectations. *New Genetics and Society* [Internet]. 2017;36(4). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706982/>

230.

Samuel GN, Farsides B. Public trust and 'ethics review' as a commodity: the case of Genomics England Limited and the UK's 100,000 genomes project. *Medicine, Health Care*

and Philosophy. 2017 Oct 30;

231.

Vaithinathan AG, Asokan V. Public health and precision medicine share a goal. *Journal of Evidence-Based Medicine*. 2017 May;10(2):76-80.

232.

Griffin BH, Chitty LS, Bitner-Glindzicz M. The 100 000 Genomes Project: What it means for paediatrics. *Archives of disease in childhood - Education & practice edition*. 2017 Apr;102(2):105-7.

233.

Evers MM, Toonen LJA, van Roon-Mom WMC. Antisense oligonucleotides in therapy for neurodegenerative disorders. *Advanced Drug Delivery Reviews*. 2015 June;87:90-103.

234.

Karin E. Lundin. Oligonucleotide Therapies: The Past and the Present. *Human Gene Therapy [Internet]*. 2015;26(8). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4554547/>

235.

Khorkova O, Wahlestedt C. Oligonucleotide therapies for disorders of the nervous system. *Nature Biotechnology*. 2017 Mar;35(3):249-63.

236.

Aartsma-Rus A. Overview on AON Design. In: Aartsma-Rus A, editor. *Exon Skipping [Internet]*. Totowa, NJ: Humana Press; 2012. p. 117-29. Available from: http://link.springer.com/10.1007/978-1-61779-767-5_8

237.

Rossor AM, Reilly MM, Sleight JN. Antisense oligonucleotides and other genetic therapies made simple. *Practical Neurology*. 2018 Feb 17;

238.

Wood N. Neurogenetics [Internet]. Cambridge: Cambridge University Press; 2012. Available from: <http://ebooks.cambridge.org/ref/id/CBO9781139087711>

239.

Clarke C, Howard R, Rossor M, Shorvon S, editors. Neurology [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2016. Available from: <http://doi.wiley.com/10.1002/9781118486160>

240.

OMIM - Online Mendelian Inheritance in Man [Internet]. Available from: <https://www.omim.org/>

241.

Teboul L, Hérault Y, Smith C, Whitelaw B. Introduction to Mammalian Genome Special Issue: Genome Editing. Mammalian Genome. 2017 Aug;28(7-8):235-6.

242.

Fernández A, Josa S, Montoliu L. A history of genome editing in mammals. Mammalian Genome. 2017 Aug;28(7-8):237-46.

243.

Marie-Christine Birling. Modeling human disease in rodents by CRISPR/Cas9 genome editing. Mammalian Genome [Internet]. 2017;28(7). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569124/>

244.

Greenfield A. Editing mammalian genomes: ethical considerations. Mammalian Genome. 2017 Aug;28(7-8):388-93.

245.

Addgene: CRISPR Guide [Internet]. Available from: <https://www.addgene.org/crispr/guide/>

246.

MGI-Mouse Genome Informatics -The international database resource for the laboratory mouse [Internet]. Available from: <http://www.informatics.jax.org/>

247.

Rossor AM, Tomaselli PJ, Reilly MM. Recent advances in the genetic neuropathies. *Current Opinion in Neurology*. 2016 Sept;

248.

Rossor AM, Evans MRB, Reilly MM. A practical approach to the genetic neuropathies. *Practical Neurology*. 2015 June;15(3):187-98.